Description

Diethyl n-[5-[n-[(3,4-Dihydro-2-Methyl-4-Oxo-6-Quinazolinyl)Methyl]-n-Methylamino]-2-Thenoyl]-L-Glutamate is a high-purity, advanced pharmaceutical intermediate of significant commercial and research interest. This compound is valued for its role as a key building block in the synthesis of complex therapeutic agents, particularly in oncology and targeted drug development. It is primarily sought by pharmaceutical R&D laboratories, fine chemical manufacturers, and academic institutions engaged in medicinal chemistry and process development.

Application

• Pharmaceutical Intermediate: Critical precursor in the synthesis of novel quinazoline-based small molecule inhibitors and targeted cancer therapies.
• Medicinal Chemistry Research: Used as a core scaffold for structure-activity relationship (SAR) studies and lead optimization in drug discovery programs.
• Process Development: Serves as a reference standard and starting material for scaling up API (Active Pharmaceutical Ingredient) manufacturing processes under GMP conditions.
• Biochemical Research: Potential tool compound for studying enzyme inhibition and cellular signaling pathways in academic and industrial research settings.
• Custom Synthesis: Building block for contract research organizations (CROs) and CDMOs (Contract Development and Manufacturing Organizations) producing bespoke compounds for clients.

Basic Information

Product Name	Diethyl n-[5-[n-[(3,4-Dihydro-2-Methyl-4-Oxo-6-Quinazolinyl)Methyl]-n-Methylamino]-2-Thenoyl]-L-Glutamate
CAS No.	132463-02-6
Molecular Formula	C27H32N4O6S
Molecular Weight	540.64 g/mol
Synonyms	Diethyl N-[5-[[(3,4-Dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thenoyl]-L-glutamate; L-Glutamic acid, N-[5-[[(3,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thenoyl]-, diethyl ester; AG 1478 precursor; Tyrphostin AG 1478 intermediate; EGFR inhibitor intermediate; Quinazoline glutamate derivative
EINECS	Contact for details

Quality Control

Our Diethyl n-[5-[n-[(3,4-Dihydro-2-Methyl-4-Oxo-6-Quinazolinyl)Methyl]-n-Methylamino]-2-Thenoyl]-L-Glutamate is manufactured under strict quality systems to ensure batch-to-batch consistency and high purity suitable for research and development. All batches are accompanied by a comprehensive Certificate of Analysis (COA) detailing purity, identity, and impurity profiles. We support compliance with relevant guidelines for advanced pharmaceutical intermediates.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This material is hygroscopic (moisture-sensitive) and light-sensitive; therefore, containers must be kept tightly sealed in a dry environment and handled under conditions that minimize exposure to ambient light and humidity to maintain stability and purity.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single impurity ≤ 1.0%
Water Content (KF)	≤ 0.5%
Residue on Ignition	≤ 0.1%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.